Equipment liquidation Leverage recent asset divestiture and Branford Group activity to target buyers of late-model lab equipment, with post-sale services such as appraisal, decommissioning, and installation for other pharma labs.

Specialty pharma partnerships Akorn's emphasis on ophthalmics and injectables, along with existing R&D capabilities and global facilities, suggests opportunities for contract manufacturing, formulation development, or private-label deals with pharma companies seeking to expand in these in-demand dosage forms.

Quality and compliance The 2023 recall events indicate demand for robust quality systems, recall planning, and regulatory remediation; position with pharma peers to offer QA/QC, serialization, and compliance consulting.

Global manufacturing footprint Multi-region manufacturing footprint can be attractive for partners seeking regional production for ophthalmics or injectables, supporting supply chain resilience and faster timelines in North America and Europe.

Portfolio optimization Historical asset sales and Chapter 7 proceedings point to opportunities to engage restructuring firms or buyers for portfolio optimization, licensing, or IP monetization related to Akorn's former product lines.